---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-070333"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2024-03-19T23:59:59+00:00"
generated_at: "2026-06-04T13:36:45.248932+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Eliem receives non-binding term sheet to acquire biotech Tango for $20M in stock

## Summary
- RA Capital owns ~47.5% of Eliem and majority of Tango; special committee oversees strategic review.
- Eliem valued at $110M, Tango at $20M; post-deal Tango holders get 15.4% of combined entity.
- Concurrent PIPE financing to be sized by parties; RA Capital expected to participate.
- Deal requires approval of majority of Eliem shares not held by RA Capital (non-waivable condition).
- Non-binding; subject to due diligence, definitive agreement, and independent committee clearance.

## SEC filing metadata
- accession: 0001193125-24-070333
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2024-03-19T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000119312524070333/0001193125-24-070333-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000119312524070333/d784366d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-070333
- JSON: https://secwatch.observer/filing/0001193125-24-070333.json
- Plain text: https://secwatch.observer/filing/0001193125-24-070333.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.